B vs CRH

The Advanced Deterministic Scorecard reveals a mixed financial profile: the Piotroski F-Score of 4/9 indicates borderline financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong profitability and growth metrics—evidenced by 23.2% YoY revenue growth and 175.7% earnings growth—the stock trades above its Graham Number of $26.91 at $51.08, reflecting rich valuation. Solid balance sheet metrics like a 0.14 Debt/Equity ratio and 2.94 Current Ratio support resilience, but weak technical trend (10/100) and inconsistent analyst targets temper bullishness. The stock's premium valuation appears justified by strong historical performance and sector outperformance, yet sustainability depends on maintaining high growth and disciplined capital allocation.

CRH exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and financial stability. While the current price of $118.00 trades at a significant premium to its Graham Number ($66.71), it remains well below its growth-based intrinsic value of $162.54. The company is outperforming its sector in valuation (P/E 21.42 vs Sector Avg 37.99) and profitability, supported by an impressive 48.4% YoY earnings growth. Despite a bearish technical trend, the strong analyst consensus and healthy balance sheet suggest a compelling long-term value proposition.